Rifaximin (Xifaxan)

Description

Rifaximin is a minimally absorbed, broad-spectrum antibiotic that belongs to the rifamycin class of antimicrobial agents. In colorectal cancer treatment, rifaximin serves as supportive care to manage treatment-related gastrointestinal complications. It is specifically used to treat bowel dysfunction following anterior resection surgery for rectal cancer and to prevent radiation-induced diarrhea in cancer patients undergoing radiotherapy.

Mechanism of Action

Rifaximin works by binding to the beta-subunit of bacterial DNA-dependent RNA polymerase, inhibiting bacterial RNA synthesis and reducing pathogenic bacterial overgrowth in the gastrointestinal tract. Its minimal systemic absorption allows it to act locally in the gut, modulating the intestinal microbiome without significant systemic effects. This localized antimicrobial action helps restore normal bowel function and reduces inflammation-related diarrhea.

Molecular Targets

Side Effects

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials